

Table SI. Characteristics of the 5 patients with trichoepitheliomas treated by topical rapamycin

Pat. No.	Sex/ Age, years	Age at onset of the disease, years	CYLD mutation	Family history	Other treatments before RPM therapy	Location of the TEP	Number estimated of TEP	Size of the TEP (mm)	Thickness of the TEP (mm)	Adverse effects		VAS EF-PH (/10)		VAS EF-PT (/10)		VAS TL-PT (/10)	
										Head-ache	Slight skin irritation	M2	M5	M2	M5	M2	M5
1	F/46	15	NE	+	CO ₂ L	Forehead	200	4	2	+	+	1	3.5	5	6	9	10
2	F/38	12	NE	+	CO ₂ L	Forehead	500	3	3	+	+	2	4	6	5.5	9	10
3	F/54	20	NE	+	CO ₂ L	Ala of nose	100	2-4	3	-	+	1	3	6	4.5	7	4
4	F/26	4	NE	+		Nasolabial fold	50	3	2	-	+	3	5	6	6	10	10
5	F/45	23	+	-	CO ₂ L IM, AC	Nasolabial fold, forehead, chin, cheeks	120	3-5	2	-	-	0	0	0	0	9	9

AC: acitretin; CO₂L: CO₂ laser; EF-PH: efficacy evaluated by the physician; EF-PT: efficacy evaluated by the patient; IM: imiquimod 5%; NE: not evaluated; RPM: rapamycin; M: months; TEP: trichoepitheliomas; TL-PT: tolerance evaluated by the patient; VAS: visual analogue scale; Y: years.